Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Competition Heats Up For Beijing’s Vaccine Market

This article was originally published in PharmAsia News

Executive Summary

Beijing, the first city to initiate free hepatitis A vaccination for children under China's nationwide immunity plan, has given the green light to GlaxoSmithKline and local enterprise Sinovac Biotech to provide inactivated hepatitis A vaccine. The two companies will effectively corner the Beijing free hepatitis A vaccine market for three years. According to public information, Sanofi Pasteur, GSK and Merck Sharpe & Dhome supply half of the paid vaccine market in the city. Officials at the China Association of Pharmaceutical Commerce believe foreign corporations will face fierce competitive bidding from domestic companies. Last year, Sanofi Pasteur was the only multinational company out of five pharmaceutical firms who won the tender for supplying Beijing with flu vaccine. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel